2NCCN Guidelines. Non-Hodgkin' s Lymphomas. Version 2. 2015.
3Zhang T,Cao L,Xie J,et al. Efficiency of CD19 chimeric antigen recep- tor-modified T cells for treatment of B cell malignancies in phase I clini- cal trials: a meta-analysis [ J ]. Oncotarget, 2015,10. [ Epub ahead of print ].